Key points are not available for this paper at this time.
“Given the large amount of overlapping cardiorenal benefits from these medications in this study, a combination of SGLT2 inhibitors and GLP-1 receptor agonist therapy is an important consideration. Because these agents differ with regard to glycemic control, weight loss, and select kidney and card...”
Edmonston et al. (Thu,) studied this question.